Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polycarbophil calcium is a synthetic, bulk-forming laxative and antidiarrheal agent developed and marketed by Zhejiang Zuoli Pharmaceutical, often under the brand name Shu Ke. As a hydrophilic polymer, it is not absorbed by the gastrointestinal tract but instead acts locally within the intestinal lumen. In the management of constipation, polycarbophil calcium absorbs water to increase stool bulk and moisture, which stimulates peristalsis and facilitates easier evacuation. In the management of diarrhea, it absorbs excess free water to increase the consistency of the stool. It is primarily indicated for the symptomatic treatment of chronic constipation and irritable bowel syndrome (IBS) characterized by either constipation or diarrhea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polycarbophil calcium.